All Oncology News

The OncLive® News page includes the latest in clinical oncology news, including breaking regulatory decisions, clinical trial findings, pivotal and practice-changing data published in academic peer-reviewed journals, and more across solid and hematologic malignancies. Regulatory news includes new drug approvals by the FDA and European Union, priority review and breakthrough therapy designations, and orphan drug and fast track statuses.

Fox Chase Cancer Center’s Austin Williams Named 2025 Society of Surgical Oncology Presidential Scholar

February 3rd 2025

Austin D. Williams, MD, MSEd, FACS, was recently named a Presidential Scholar by the Society of Surgical Oncology.

CHMP Recommends Approval of Durvalumab for Limited-Stage Small Cell Lung Cancer

February 3rd 2025

The CHMP has recommended approval for durvalumab in limited-stage small cell lung cancer following platinum-based chemoradiation.

FDA Accepts BLA for Pertuzumab Biosimilar in HER2+ Breast Cancer

February 3rd 2025

The FDA accepted a BLA seeking the approval of the pertuzumab biosimilar HLX11 for HER2-positive breast cancer.

Encorafenib/Cetuximab Plus Chemo Improves Survival in BRAF V600E+ mCRC

February 3rd 2025

Encorafenib plus cetuximab and mFOLFOX6 improved PFS and OS vs chemotherapy in BRAF V600E–mutant metastatic colorectal cancer.

FDA Approves Companion Diagnostic for T-DXd in HER2-Ultralow Metastatic Breast Cancer

February 3rd 2025

The FDA has approved a companion diagnostic for trastuzumab deruxtecan in hormone receptor–positive, HER2-ultralow metastatic breast cancer.

A Road Map for Change Report Provides a Guide to Elevate Breast Cancer Care

February 3rd 2025

Coauthor of the Lancet Breast Cancer Commission report, Reshma Jagsi, MD, DPhil, details the 6 themes of the evidence-based plan aimed to address challenges in the field.

Neoadjuvant Botensilimab Plus Balstilimab Yields High MPR Rates in CRC

February 3rd 2025

The combination of botensilimab plus balstilimab elicited high major pathologic response rates with extended time to surgery in resectable colorectal cancer.

Comparable Survival Outcomes Observed With Atezolizumab/Bevacizumab vs Tremelimumab/Durvalumab in First-Line HCC

February 3rd 2025

Clinical outcomes did not significantly differ with atezolizumab plus bevacizumab vs tremelimumab and durvalumab in treatment-naive, unresectable HCC.

Shields Spotlights Lessons Learned in Limited-Stage SCLC and Areas Ripe for Further Research

February 2nd 2025

Misty Shields, MD, PhD, provides a comprehensive overview of key updates in. the management of limited-stage small cell lung cancer.

Five Under 5: Top Oncology Videos for the Week of 1/26

February 2nd 2025

The top 5 videos of the week cover insights in gastrointestinal cancers, gynecologic malignancies, and blood cancers.

Expanded Targets, Synergistic Regimens Are Needed to Propel NSCLC Beyond Anti–PD-1 Therapy

February 2nd 2025

Melissa L. Johnson, MD, discusses the evolution of immunotherapy approaches beyond PD-1 inhibition in lung cancer.

Data Help Refine Optimal Radiotherapy Approaches in Small Cell Lung Cancer

February 1st 2025

Walter J. Curran, MD, discusses the evolving use of radiotherapy in small cell cancer and data supporting its optimal use.

The OncFive: Top Oncology Articles for the Week of 1/26

February 1st 2025

T-DXd wins FDA approval in HER2-low and -ultralow breast cancer, 177 Lutetium edotreotide boosts PFS in GEP-NETS, and more from OncLive this week.

Retrospective Data Highlight FRα and B7-H4 as Potential ADC Targets in Endometrial Cancer

February 1st 2025

A retrospective analysis showed a high proportion of endometrial cancer samples expressed FRα or B7-H4.

ADC Development in Ovarian Cancer: What's Next for FRa and Beyond?

January 31st 2025

Kathleen Moore, MD, MD, FASCO, discusses the development of antibody-drug conjugates in ovarian cancer and how they could shift the field.

Dr Naumann on Next-Generation Antibody-Drug Conjugates in Ovarian Cancer

January 31st 2025

R. Wendel Naumann, MD, discusses next-generation antibody-drug conjugates in ovarian cancer.

Dr Lheureux on the Evolution of ADCs Since Mirvetuximab Soravtansine in Ovarian Cancer

January 31st 2025

Stéphanie Lheureux, MD, PhD, discusses the evolution of antibody-drug conjugates since mirvetuximab soravtansine in ovarian cancer.

Trend Towards Favorable DFS Observed With Cisplatin/Paclitaxel in HRD Advanced Ovarian Cancer

January 31st 2025

Cisplatin/paclitaxel showed trend towards improved DFS vs cisplatin alone in advanced-stage ovarian cancer.

Datopotamab Deruxtecan Wins CHMP Positive Opinion for Previously Treated HR+ Breast Cancer

January 31st 2025

Datopotamab deruxtecan approaches approval in Europe as an option for patients with previously treated hormone receptor–positive breast cancer.

Retrospective Analysis Shows Frailty Leads to Worsened Outcomes After Surgery in Gynecologic Cancers

January 31st 2025

Postoperative outcomes may be worse among patients with gynecologic cancers who are elderly or frail.